Winton Group’s CorMedix CRMD Stock Holding History

Winton Group’s Portfolio CRMD Stock Details CRMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$511K	Buy	65,061 +26,723	+70%	+$211K	0.02%	701
2026 Q1	$260K	Buy	38,338 +16,308	+74%	+$121K	0.01%	900
2025 Q4	$256K	Sell	22,030 -3,417	-13%	-$37.8K	0.01%	778
2025 Q3	$296K	Buy	+25,447	New	+$308K	0.01%	636
2020 Q4	–	Sell	-62,455	Closed	-$377K	–	1348
2020 Q3	$377K	Buy	+62,455	New	+$314K	0.01%	1185
2019 Q3	–	Sell	-10,058	Closed	-$90K	–	1556
2019 Q2	$90K	Buy	+10,058	New	+$78.9K	﹤0.01%	1085

Other funds holding CRMD

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

OAM

Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Winton Group's CRMD Position: Q2 2026 in Review

Winton Group increased its CorMedix (CRMD) stake by 70% in Q2 2026, buying an estimated $211K and bringing the position to 65,061 shares worth $511K. The position accounts for 0.02% of the portfolio, ranked #701.

Winton Group first reported a position in CRMD in Q2 2019 and has held it in 6 quarters since. 194 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

Winton Group held 65,061 shares of CorMedix worth $511K as of Q2 2026.
Winton Group bought 26,723 CorMedix shares in Q2 2026, an estimated $211K.
CorMedix made up 0.02% of Winton Group's portfolio in Q2 2026, its #701 holding.
Winton Group first reported a position in CorMedix in Q2 2019 and has held it in 6 quarters since.
194 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Winton Group's 13F filing for Q2 2026, filed 7 Aug 2026.